Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion type Assertion NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_head.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion wasGeneratedBy ECO_0000218 NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion wasDerivedFrom ctd_human-20150221 NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion SIO_000772 15248218 NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion evidence source_evidence_curated NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.
- NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_assertion description "[Patients who were either heterozygous or homozygous for CYP2C19*2 had a significantly lower risk of developing premature ovarian failure (relative risk 0.10; 95% confidence interval 0.02-0.52), after adjustment for age and total number of cyclophosphamide pulses received.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP12172.RAbtPyWkLAI_xKfxEJFhn1a6tnPxmYqGhfkb-IgUVCkX8130_provenance.